These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 7586928)

  • 1. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
    Fromm MF; Hofmann U; Griese EU; Mikus G
    Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
    Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
    Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine.
    Kirkwood LC; Nation RL; Somogyi AA
    Br J Clin Pharmacol; 1997 Dec; 44(6):549-55. PubMed ID: 9431830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
    Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA
    Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affinities of dihydrocodeine and its metabolites to opioid receptors.
    Schmidt H; Vormfelde Sv; Klinder K; Gundert-Remy U; Gleiter CH; Skopp G; Aderjan R; Fuhr U
    Pharmacol Toxicol; 2002 Aug; 91(2):57-63. PubMed ID: 12420793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.
    Mikus G; Bochner F; Eichelbaum M; Horak P; Somogyi AA; Spector S
    J Pharmacol Exp Ther; 1994 Feb; 268(2):546-51. PubMed ID: 8113966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers.
    Wilder-Smith CH; Hufschmid E; Thormann W
    Br J Clin Pharmacol; 1998 Jun; 45(6):575-81. PubMed ID: 9663813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype.
    Mikus G; Trausch B; Rodewald C; Hofmann U; Richter K; Gramatté T; Eichelbaum M
    Clin Pharmacol Ther; 1997 Apr; 61(4):459-66. PubMed ID: 9129563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
    Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
    Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
    Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L
    Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of active metabolites in dihydrocodeine effects.
    Schmidt H; Vormfelde SV; Walchner-Bonjean M; Klinder K; Freudenthaler S; Gleiter CH; Gundert-Remy U; Skopp G; Aderjan R; Fuhr U
    Int J Clin Pharmacol Ther; 2003 Mar; 41(3):95-106. PubMed ID: 12665158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
    Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
    Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.
    Abolfathi Z; Fiset C; Gilbert M; Moerike K; Bélanger PM; Turgeon J
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1196-201. PubMed ID: 8371133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the genetic polymorphism of dihydrocodeine O-demethylation in man via analysis of urinary dihydrocodeine and dihydromorphine by micellar electrokinetic capillary chromatography.
    Hufschmid E; Theurillat R; Wilder-Smith CH; Thormann W
    J Chromatogr B Biomed Appl; 1996 Mar; 678(1):43-51. PubMed ID: 8861655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
    Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
    Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing.
    Ammon S; Hofmann U; Griese EU; Gugeler N; Mikus G
    Br J Clin Pharmacol; 1999 Sep; 48(3):317-22. PubMed ID: 10510141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study.
    Pedersen RS; Damkier P; Brosen K
    Clin Pharmacol Ther; 2005 Jun; 77(6):458-67. PubMed ID: 15961977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
    Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
    Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.